TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...
A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among ...
Zydus Lifesciences Limited, an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand ...
Rising Chronic Disease Burden, Biosimilar Insulin Adoption, and Smart Connected Pen Technologies Drive Sustained Market Expansion.Austin, United States, March 12, 2026 (GLOBE NEWSWIRE) -- As per SNS ...
Zydus Lifesciences has launched Semaglutide Injection under the brand names SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results